Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3:16:329-339.
doi: 10.2147/BCTT.S464161. eCollection 2024.

The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker

Mehmet Emin Buyukbayram  1 , Zekeriya Hannarici  1 , Yakup Duzkopru  2 , Aykut Turhan  1 , Alperen Akansel Caglar  1 , Pınar Coban Esdur  1 , Mehmet Bilici  1 , Salim Basol Tekin  1 , Doğan Yazılıtaş  2
Affiliations

The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker

Mehmet Emin Buyukbayram et al. Breast Cancer (Dove Med Press). .

Abstract

Objective: Hormone positive breast cancer is a tumor with high mortality. Combining antihormonal therapy with cyclin dependent kinase 4/6 inhibitors (CDK4/6i) has resulted in longer survival. The effect of inflammatory parameters such as c-reactive protein and c-reactive protein/lymphocyte ratio (CLR) on efficacy and survival in CDK4/6i treatment is unknown. In our study, we aimed to investigate the role of CLR and some parameters in predicting progression-free survival (PFS) with CDK4/6i.

Methods: This retrospective cohort study included 78 patients with denovo and recurrent metastatic breast cancer treated with CDK4/6i. Cut off values for the prediction of mortality by various numerical parameter scores were performed by ROC Curve analysis. The effect of clinical variables, inflammatory and histopathological parameters on survival was analyzed by Kaplan-Meier method.

Results: Neutrophil/lymphocyte ratio (NLR) and CLR were statistically significant in predicting mortality (p < 0.05). Ki67 and CLR were correlated with PFS. Age and CLR were correlated with OS (p < 0.05). CLR was statistically significant for both PFS (p = 0.022) and OS (p = 0.006).

Conclusion: In patients with metastatic hormone-positive breast cancer using CDK4/6i, low CLR and low Ki67 were correlated with longer PFS duration.

Keywords: C-reactivated protein/lymphocyte ratio; hormone-positive breast cancer; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interest exists in this work.

Figures

Figure 1
Figure 1
PFS time treatment with CDK4/6i (A), Ki67 ve PFS time (B), CLR ve PFS time (C).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551 - DOI - PubMed
    1. American Cancer Society. Breast Cancer Facts and Figures 2019–2020. Atlanta, GA: American Cancer Society; 2019.
    1. Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst. 2019;111(12):1298–1306. doi:10.1093/jnci/djz090 - DOI - PMC - PubMed
    1. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Sauer AG, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583 - DOI - PubMed
    1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). doi:10.1093/jnci/dju055 - DOI - PMC - PubMed

LinkOut - more resources